

## REMARKS

Claims 1-39 are pending. In the February 6, 2006 Office Action, the Examiner required Applicants to elect a single invention from among the following groups of allegedly distinct inventions:

- |           |   |
|-----------|---|
| Group I   | Claims 1-3, 7-10, 15, 17, 19, 20, 23, 25-33 and 35 drawn in part to a method of treating or preventing a type of cancer comprising administering to a subject a composition comprising (a) heat shock protein, and (b) antigenic proteins.                        |
| Group II  | Claims 1-3, 7-10, 15, 17, 19, 20, 23, 25-33 and 35, drawn in part to a method of treating or preventing a type of cancer comprising administering to a subject a composition comprising (a) alpha-2-macroglobulin, and (b) antigenic proteins.                    |
| Group III | Claims 4-6, 11-14, 16, 18, 21, 22, 24, 25-32, 34, and 36, drawn in part to a method of treating or preventing a type of infectious disease, comprising administering to a subject a composition comprising (a) heat shock protein, and (b) antigenic proteins.    |
| Group IV  | Claims 4-6, 11-14, 16, 18, 21, 22, 24, 25-32, 34, and 36, drawn in part to a method of treating or preventing a type of infectious disease, comprising administering to a subject a composition comprising (a) alpha-2-macroglobulin, and (b) antigenic proteins. |
| Group V   | Claims 37-39, drawn in part to a kit comprising composition comprising (a) heat shock protein and (b) antigenic proteins.   |
| Group VI  | Claims 37-39, drawn in part to a kit comprising a composition comprising (a) alpha-2-macroglobulin and (b) antigenic proteins.  |

The Examiner contended that the above Groups are distinct inventions.

The Examiner also required election of a single species from among the following: a chemotherapeutic agent, an anti-angiogenic agent, a cytokine, a biological response modifier, a hormone, an antibody, a polynucleotide, an immunostimulatory oligonucleotide, a

photodynamic therapeutic agent and radiation. In the Examiner's view, claims 1-22 and 25-36 are generic.


In response, Applicants provisionally elect, with traverse, the invention of Group II, claims 1-3, 7-10, 15, 17, 19, 20, 23, 25-33 and 35, drawn in part to a method of treating or preventing a type of cancer comprising administering to a subject a composition comprising (a) alpha-2-macroglobulin, and (b) antigenic proteins. With respect to the species election, Applicants elect the species of a chemotherapeutic agent.

Applicants understand that, should the requirement for a species election be maintained, upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim pursuant to 37 C.F.R. § 1.141. Claims readable on the elected species of "a chemotherapeutic agent" are claims 1-23 and 25-39. Claims 1-22 and 25-39 are generic.

Applicant respectfully requests that the present remarks be entered and made of record in the instant application. An early allowance of the application is earnestly requested. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Date: June 6, 2006

Respectfully submitted,

  
Adriane M. Antler 32,605  
(Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 326-3939